This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Activity
  • Evaluation
  • Claim Credit
Questions about our CME?
Questions about our CME?
Module 2: Selecting a Biologic for Long-Term Success in UC

Module 2: Selecting a Biologic for Long-Term Success in UC


Clinical Review

Time to Complete

45 minutes for AMA/40 minutes for ANCC credits


November 30, 2017


November 30, 2018
Add to Queue

Maximum Credits

0.75 / AMA PRA Category 1 Credit(s)TM
0.70 / CNE Contact Hour(s)

Accredited Provider

Jointly provided by Postgraduate Institute for Medicine and Strategic Consultants International

Commercial Supporter

Supported by an educational grant from Takeda Pharmaceuticals, U.S.A. Inc

Program Description

The traditional goal of therapy for ulcerative colitis (UC) is the induction and maintenance of (steroid-free) clinical remission. Mucosal healing has assumed increasing importance, due to the association with fewer relapses, and reduced risk of surgery and hospitalization. Choosing the ‘right’ goal for any patient requires balancing the patient’s needs with clinical efficacy and consideration of risks and costs. When selecting a biologic therapy there are no data to recommend a ‘one size fits all’ approach, therefore several aspects should be taken into consideration, such as the clinical evidence, disease severity and patient characteristics and preferences. This module presents some of the clinical evidence for biologic therapy in UC, including ‘real-world’ and long-term data, and discusses relevant factors to consider when selecting a biologic agent for a UC patient.

Intended Audience

Physicians and registered nurses

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Distinguish short-term needs (symptomatic improvement with minimal side effects) from long-term goals (continuous steroid-free clinical remission with documented mucosal healing) of therapy in UC
  • Select biologic therapy that aligns with individual patient needs to minimize risk of treatment discontinuation

Accreditor Disclosure of Conflicts of Interest Policy

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported any financial relationships or relationships to products or devices they or their spouse/life partner with commercial interests related to the content of this CME activity under the Faculty section below.


Course Author
Stephen B. Hanauer, MD

Clifford Joseph Barborka Professor of Medicine
Northwestern Feinberg School of Medicine
Chicago, IL

Dr. Hanauer discloses the following:
Clinical research support: AbbVie, Allergan, Amgen, Celgene, Genentech, Janssen, Lilly, Pfizer, Prometheus, Receptos, Takeda, UCB Pharma
Consulting fees: AbbVie, Actavis, Allergan, Amgen, Boehringer Ingelheim, Celgene, Celltrion, Ferring, Genentech, Hospira, Janssen, Lilly, Merck, Pfizer, Prometheus, Receptos, Salix, Samsung Bioepis, Seres Health, Shire, Takeda, UCB Pharma
Speaker fees: AbbVie, Janssen, Takeda

Course Director
Miguel D. Regueiro, MD

IBD Clinical Medical Director
Division of Gastroenterology, Hepatology and Nutrition
Department of Medicine
University of Pittsburgh School of Medicine
Pittsburgh, PA

Dr. Regueiro discloses the following:
Consulting Fees: Abbvie, Takeda, Amgen, Janssen, Pfizer, UCB

Joint Provider Disclosures

The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN, and Jan Schultz, RN, MSN, CHCP, have nothing to disclose. The SCI planners and managers, Ian Morgan MSc, Elena Urso BSc, and Ana Costa, PhD, have nothing to disclose.




AMA PRA Category 1 Credit(s)TM

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and polices of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Strategic Consultants International. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.




CNE Contact Hour(s)

Accreditation Statement

The Postgraduate Institute for Medicine is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Designation Statement

This educational activity for 0.70 contact hour(s) is provided by the Postgraduate Institute for Medicine.

Disclosure of Unlabeled Use

This education activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indication, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, a review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

For information about the accreditation of this program, please contact Postgraduate Institute for Medicine AT (303) 799-1930 and via email at

Privacy Policy


Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue

Related to this activity